Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
Organizer:

In this Satellite, WHO will present highlights from recent updates to the Consolidated ARV guidelines. New directions on the role of dolutegravir (DTG) based regimens in first and second line treatment, and in post-exposure prophylaxis (PEP), as well as, directions to improve early infant diagnosis will be presented. Country approaches to the implementation of dolutegravir transition and data needs to help better understand the signal of neural tube defect (NTD) risk will be explored. A panel with representation from Ministries of Health, researchers, implementers and civil society will review the implications of these new directions for HIV treatment programmes. This session will be of interest to programme managers, researchers, implementers, clinicians and civil society. Lunch will be served prior to the satellite

12:30
Welcome by co-chairs
12:40
Opening remarks from WHO Deputy Director General for Programmes
Soumnya Swaminathan, World Health Organization, Switzerland
Directions from the WHO guidelines: the role of DTG for treating and preventing HIV infection early infant diagnosis
12:45
The role of DTG based regimens in first- and second-line HIV treatment and PEP – new directions and approaches for use
Meg Doherty, World Health Organization, Switzerland
13:00
What we know about the signal of risk of neural tube defects with DTG use at conception
Lynne Mofenson, Elizabeth Glaser Pediatric AIDS Foundation, United States
13:10
Opportunities for the use of new ARVs for infants, children and adolescents and updated guidance on early infant diagnosis (NAT)
Martina Penazzato, World Health Organization (WHO), Switzerland
13:20
Q&A
Panel Discussion: Implementation of DTG in light of WHO new directions and the signal of risk for NTD - How to scale up treatment, respect client choice and monitor for risk
13:30
Views from Botswana’s Country Programme
Tendani Gaolathe, BCCP and Harvard-Botswana AIDS Initiative, Botswana
13:35
Views from women seeking HIV treatment
Florence Anam, The International Community of Women Living with HIV (ICW), Kenya
13:40
PEPFAR - a driver of the DTG transition in high burden countries
Ambassador Deborah Birx, U.S. Department of State, Office of the Global AIDS Coordinator and Health Diplomacy, United States
13:45
The Global Fund – supporting ARV procurement around the globe
Sam Kunii, Global Fund, Switzerland
13:50
Views from Brazil’s Country Programme
Adele Benzaken, Ministry of Health, Brazil
13:55
Views from clients from different epidemics
Martin Choo, KLASS, Malaysia
14:00
Views from Kenya’s Country Programme
Evelyn Muthoni, Kenya Ministry of Health, Kenya
14:05
Innovators of new medicines and diagnostics
Lelio Marmora, Unitaid, Switzerland
14:10
Q&A
14:25
Closing remarks